ReviewNeuropsychology review2014
Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan.
Review in Neuropsychology review, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 84 citations in OpenAlex.
- Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.Human brain mapping · 2018Trial
- Cognitive functioning predicts vulnerability to financial exploitation in APOE e4 carriers.International psychogeriatrics · 2025Article
- APOE ε4-related differences in brain structure, function, and connectivity at midlife: A scoping review.The journal of prevention of Alzheimer's disease · 2025Article
- APOE ε4 carriers share immune-related proteomic changes across neurodegenerative diseases.Nature medicine · 2025Article
- Voxel-wise insights into early Alzheimer's disease pathology progression: the association with APOE and memory decline.GeroScience · 2025Article
- Layer-Dependent Effect of Aβ-Pathology on Cortical Microstructure With Ex Vivo Human Brain Diffusion MRI at 7 Tesla.Human brain mapping · 2025Article
- Proteome profiling of cerebrospinal fluid using machine learning shows a unique protein signature associated with APOE4 genotype.Aging cell · 2025Article
- Proteome profiling of cerebrospinal fluid using machine learning shows a unique protein signature associated with APOE4 genotype.bioRxiv : the preprint server for biology · 2024Article
- Link among apolipoprotein E E4, gait, and cognition in neurodegenerative diseases: ONDRI study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Sex significantly predicts medial temporal volume when controlling for the influence of ApoE4 biomarker and demographic variables: A cross-ethnic comparison.Journal of the International Neuropsychological Society : JINS · 2024Article
- Biomarkers of Alzheimer's disease in Black and/or African American Alzheimer's Disease Neuroimaging Initiative (ADNI) participants.Neurobiology of aging · 2023Article
- Annualized changes in rate of amyloid deposition and neurodegeneration are greater in participants who become amyloid positive than those who remain amyloid negative.Neurobiology of aging · 2023Article
- Alzheimer's disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals.Alzheimer's research & therapy · 2023Article
- Genotypic effects of APOE-ε4 on resting-state connectivity in cognitively intact individuals support functional brain compensation.Cerebral cortex (New York, N.Y. : 1991) · 2023Article
- Effect of APOE ε4 genotype on amyloid-β, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment.European journal of neurology · 2023Article
- Rates of β-amyloid deposition indicate widespread simultaneous accumulation throughout the brain.Neurobiology of aging · 2022Article
- Accelerated functional brain aging in pre-clinical familial Alzheimer's disease.Nature communications · 2021Article
- DHA intake relates to better cerebrovascular and neurodegeneration neuroimaging phenotypes in middle-aged adults at increased genetic risk of Alzheimer disease.The American journal of clinical nutrition · 2021Article
- Nonlinear interaction between APOE ε4 allele load and age in the hippocampal surface of cognitively intact individuals.Human brain mapping · 2021Article
- APOE-ε4-related differences in left thalamic microstructure in cognitively healthy adults.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ε4 allele of the apolipoprotein E (APOE4) is associated with an increased risk of developing Alzheimer's disease (AD). Hence, several studies have compared the brain characteristics of APOE4 carriers versus non-carriers in presymptomatic stages to determine early AD biomarkers. The present review provides an overview on APOE4-related brain changes in cognitively normal individuals, focusing on the main neuroimaging biomarkers for AD, i.e. cortical beta-amyloid (Aβ) deposition, hypometabolism and atrophy. The most consistent findings are observed with Aβ deposition as most studies report significantly higher cortical Aβ load in APOE4 carriers compared with non-carriers. Fluorodeoxyglucose-positron emission tomography studies are rare and tend to show hypometabolism in brain regions typically impaired in AD. Structural magnetic resonance imaging findings are the most numerous and also the most discrepant, showing atrophy in AD-sensitive regions in some studies but contradicting results as well. Altogether, this suggests a graded effect of APOE4, with a predominant effect on Aβ over brain structure and metabolism. Multimodal studies confirm this view and also suggest that APOE4 effects on brain structure and function are mediated by both Aβ-dependent and Aβ-independent pathological processes. Neuroimaging studies on asymptomatic APOE4 carriers offer relevant information to the understanding of early pathological mechanisms of the disease, although caution is needed as to whether APOE4 effects reflect AD pathological processes, and are representative of these effects in non-carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.